Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06171139 · ClinicalTrials.gov registry record · NA

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

A NA study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06171139 is a NA study of Prostate Cancer and Prostate Cancer Metastatic that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06171139, a NA study of Prostate Cancer and Prostate Cancer Metastatic, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.

Interventions

  • OTHER Questionnaires
  • OTHER Counseling Tool

Study Locations (1)

California

  • University of California - San Francisco

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-12-01
Est. Completion 2027-08-31
Phase NA

What the Registry Record Tells You About NCT06171139

The ClinicalTrials.gov registry entry for NCT06171139 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.

NCT06171139 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06171139 about?

NCT06171139 is a clinical study titled "Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer". The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.

What is the current status of trial NCT06171139?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-12-01. Estimated completion is 2027-08-31.

What conditions does trial NCT06171139 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Metastatic.

What interventions are being tested in trial NCT06171139?

The interventions under investigation include: Questionnaires (OTHER), Counseling Tool (OTHER).

Who is sponsoring clinical trial NCT06171139?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06171139 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.